VEGF serum concentrations in patients with long bone fractures: a comparison between impaired and normal fracture healing.
Vascular endothelial growth factor (VEGF) plays an important role in the bone repair process as a potent mediator of angiogenesis and it influences directly osteoblast differentiation. Inhibiting VEGF suppresses angiogenesis and callus mineralization in animals. However, no data exist so far on systemic expression of VEGF with regard to delayed or failed fracture healing in humans. One hundred fourteen patients with long bone fractures were included in the study. Serum samples were collected over a period of 6 months following a standardized time schedule. VEGF serum concentrations were measured. Patients were assigned to one of two groups according to their course of fracture healing. The first group contained 103 patients with physiological fracture healing. Eleven patients with delayed or nonunions formed the second group of the study. In addition, 33 healthy volunteers served as controls. An increase of VEGF serum concentration within the first 2 weeks after fracture in both groups with a following decrease within 6 months after trauma was observed. Serum VEGF concentrations in patients with impaired fracture healing were higher compared to the patients with physiological healing during the entire observation period. However, statistically significant differences were not observed at any time point between both groups. VEGF concentrations in both groups were significantly higher than those in controls. The present results show significantly elevated serum concentrations of VEGF in patients after fracture of long bones especially at the initial healing phase, indicating the importance of VEGF in the process of fracture healing in humans.
Sarahrudi
Kambiz
K
Department of Traumatology, Medical University of Vienna, Waehringer Guertel 18-20, A- 1090 Vienna, Austria.
Thomas
Anita
A
Braunsteiner
Tomas
T
Wolf
Harald
H
Vécsei
Vilmos
V
Aharinejad
Seyedhossein
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D005264:Femoral Fractures / Q000097:blood* / Q000503:physiopathology / Q000601:surgery; D017102:Fracture Healing / Q000502:physiology*; D005599:Fractures, Ununited / Q000097:blood* / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D006810:Humeral Fractures / Q000097:blood* / Q000503:physiopathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D015415:Biomarkers; D042461:Vascular Endothelial Growth Factor A